Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Harald Tammen"'
Autor:
Harald Tammen, Martin Kömhoff, Denis Delić, Søren S. Lund, Berthold Hocher, Sandra Frankenreiter, Rüdiger Hess, Maximilian von Eynatten, Michael Mark, Thomas Klein
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes, with additional beneficial effects for the kidney. Treatment of mice with linagliptin revealed increased storage of cobalamin (Cbl, Vitamin
Externí odkaz:
https://doaj.org/article/a1b0f7ec227a4026ad07550aff7ba47f
Autor:
Henrik H. Hansen, Rikke V. Grønlund, Tamara Baader-Pagler, Peter Haebel, Harald Tammen, Leif Kongskov Larsen, Jacob Jelsing, Niels Vrang, Thomas Klein
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Dipeptidyl peptidase IV (DPP-IV) inhibitors improve glycemic control by prolonging the action of glucagon-like peptide-1 (GLP-1). In contrast to GLP-1 analogues, DPP-IV inhibitors are weight-neutral. DPP-IV cleavage of PYY and NPY gives rise
Externí odkaz:
https://doaj.org/article/97a3ac05b965484c814efcbeef1dbf0b
Autor:
Fausto Chiazza, Harald Tammen, Hiranya Pintana, Grazyna Lietzau, Massimo Collino, Thomas Nyström, Thomas Klein, Vladimer Darsalia, Cesare Patrone
Publikováno v:
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-13 (2018)
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are approved drugs for the treatment of hyperglycemia in patients with type 2 diabetes. These effects are mainly mediated by inhibiting endogenous glucagon-like peptide-1 (GLP-1
Externí odkaz:
https://doaj.org/article/8aea2e3d84d74e568768d9f7012ce3f9
Autor:
Michael Mark, Denis Delic, Thomas Klein, Elisa Benetti, Harald Tammen, Maximilian von Eynatten, Cornelia Schepers
Publikováno v:
Diabetes, Obesity and Metabolism. 23:1968-1972
Results of a post hoc analysis of urinary dipeptidyl peptidase-4 (DPP-4) protein as a predictor of urine albumin-to-creatinine ratio (UACR) response to linagliptin treatment based on MARLINA-T2D trial data are described. MARLINA was a 24-week, phase
Autor:
Leif K. Larsen, Henrik H. Hansen, Jacob Jelsing, Harald Tammen, Niels Vrang, Peter W. Haebel, Rikke V. Grônlund, Thomas Klein, Tamara Baader-Pagler
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Dipeptidyl peptidase IV (DPP-IV) inhibitors improve glycemic control by prolonging the action of glucagon-like peptide-1 (GLP-1). In contrast to GLP-1 analogues, DPP-IV inhibitors are weight-neutral. DPP-IV cleavage of PYY and NPY gives rise to PYY3-
Autor:
Fausto Chiazza, Hiranya Pintana, Massimo Collino, Cesare Patrone, Thomas Nyström, Vladimer Darsalia, Grazyna Lietzau, Harald Tammen, Thomas W. Klein
Publikováno v:
Diabetes. 67
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) decrease hyperglycemia by inhibiting glucagon-like peptide-1 (GLP-1) cleavage. Gliptins can also improve stroke outcome in rodents independently of GLP-1R. However, the underlying mechanisms are un
Autor:
Hiranya Pintana, Massimo Collino, Thomas Klein, Harald Tammen, Thomas Nyström, Fausto Chiazza, Grazyna Lietzau, Cesare Patrone, Vladimer Darsalia
Publikováno v:
Cardiovascular Diabetology
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-13 (2018)
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-13 (2018)
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are approved drugs for the treatment of hyperglycemia in patients with type 2 diabetes. These effects are mainly mediated by inhibiting endogenous glucagon-like peptide-1 (GLP-1) cleavag
Autor:
Berthold Hocher, Harald Tammen, Denis Delic, Mohamed M S Gaballa, Christoph Reichetzeder, Oleg Tsuprykov, Burkhard Kleuser, Jingli Guo, Shufei Zeng, Karoline von Websky, Thomas Klein, Ahmed A. Hasan
Publikováno v:
Kidney international. 95(6)
Dipeptidyl peptidase type 4 (DPP-4) inhibitors were reported to have beneficial effects in experimental models of chronic kidney disease. The underlying mechanisms are not completely understood. However, these effects could be mediated via the glucag
Autor:
Harald, Tammen, Rüdiger, Hess
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1719
Mass spectrometric (MS) comparative analysis of peptides in biological specimens (nontargeted peptidomics) can result in large amounts of data due to chromatographic separation of a multitude of samples and subsequent MS analysis of numerous chromato
Autor:
Harald Tammen, Rüdiger Hess
Publikováno v:
Methods in Molecular Biology ISBN: 9781493975365
Mass spectrometric (MS) comparative analysis of peptides in biological specimens (nontargeted peptidomics) can result in large amounts of data due to chromatographic separation of a multitude of samples and subsequent MS analysis of numerous chromato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f526da678bd86d3f7689b8eccc805660
https://doi.org/10.1007/978-1-4939-7537-2_12
https://doi.org/10.1007/978-1-4939-7537-2_12